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and glatiramer acetate) vs. conventional therapy for treatment of
MS. METHODS: Search of electronic databases has identiﬁed 8
models. We evaluated the following sources of uncertainty: 1)
variation in population characteristics (age, gender, country); 2)
sources of data on effectiveness, costs, and health preferences; 3)
modeling assumptions (choice and duration of treatment, long-
term treatment effectiveness, time of treatment initiation and ter-
mination); and 4) model structure (number of health states, study
horizon, and modeling software). RESULTS: Results for inter-
feron beta-1a varied from cost-saving to $2,558,660 (2005 US$)
per quality adjusted of life year (QALY), CE of interferon beta-
1b varied from $10,629/QALY to dominated (more costly and
less effective), and results for glatiramer acetate varied from
$165,201/QALY to dominated. Time horizon and treatment
duration varied from 2 years to lifetime. Studies with longer
treatment duration reported worse (higher) CE. All studies 
used country-speciﬁc cost data and performed some sensitivity
analyses, but only 4 models were evaluated for uncertainty.
CONCLUSIONS: Two out of 8 models found interferons cost-
effective, while glatiramer acetate was not CE based on societal
standards. The differences in models’ results were attributed to
the lack of evidence on long-term treatment effectiveness 
and variation in modeling approaches. Use of DMAs could be
justiﬁed for selected subpopulations, if prices were reduced, 
or if more information on long-term treatment effect becomes
available.
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OBJECTIVE: Migraine is a chronic, episodic condition that
places a tremendous burden on the health care system, employ-
ers, patients and families. This study compared the cost-
effectiveness of treating a migraine with one dose of eletriptan
40mg or sumatriptan 100mg during a 24-hour period.
METHODS: This study used data from a randomized, placebo-
controlled trial to compare the cost-effectiveness of eletriptan 40
mg and sumatriptan 100mg in treating acute migraine. Three
effectiveness measures were compared (sustained headache
response at 1 and 2 hours, and sustained pain-free response at
2 hours) over a 24-hour period in deﬁning treatment success. The
total cost of treating all evaluable patients was deﬁned as the
total cost of the triptans used by patients up to 24 hours after
the ﬁrst dose. The cost per successfully treated patient (CPSTP)
was calculated for each of the three deﬁnitions of treatment
success using the following formula: [CPSTP = Total triptan cost
of treating evaluable patients/ Number of successfully treated
patients] RESULTS: For the 1-hour sustained headache response,
the CPSTP estimates were $103 (95% CI: $89–122) for eletrip-
tan and $149 (95% CI: $126–177) for sumatriptan. For the 2-
hour sustained headache response, the estimates were $48 (95%
CI: $44–53) and $67 (95% CI: $60–76) for eletriptan and suma-
triptan, respectively. For the 2-hour sustained pain-free response,
the estimates were $90 (95% CI: $79–105) for eletriptan and
$151 (95% CI: $127–181), for sumatriptan. The beneﬁt of
eletriptan 40mg over sumatriptan 100mg is clear for all three
measures of success. CONCLUSIONS: The CPSTP, calculated
for each effectiveness measure, was consistently lower for eletrip-
tan 40mg versus sumatriptan 100mg. These results support 
the use of eletriptan 40mg over sumatriptan 100mg in acute
migraine management, and can be used to assist decision makers
in formulary considerations.
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OBJECTIVES: Examine patterns of published economic “value
messages” for anti-epileptic drugs (AEDs). METHODS: Using
literature review best practices, identiﬁed, reviewed, and
abstracted data from comparative economic analyses published
in English and referenced in PubMed or presented at ISPOR. For
each study, documented comparators, “winners” and “losers”,
explanation of economic advantage (if any) study sponsor (if
any), year published, country of interest, and study design.
RESULTS: We identiﬁed 26 studies containing at least one com-
parative economic “value message” for an AED. A total of 57%
(15) were published as manuscripts; 53% (14 of 26) were spon-
sored by a drug manufacturer (4 manuscripts and 10 conference
abstracts); and 38% (10 of 26) were US-oriented. Of the 14
sponsored studies, Ortho-McNeil (topiramate) sponsored 6
(only 1 published; only 1 US-oriented); UCB (levetiracetam) 4;
Novartis (carbamazepine, oxcarbazepine) 3; and GSK (lamot-
rigine) 1. With only one exception (Ortho-McNeil), sponsored
studies generated positive messages for sponsors’ products. The
26 studies generated 39 comparative messages. There was at
least one “winning” message for 11 of the 13 AEDs studied. Top-
iramate was the most frequent “winner” (35% of all messages
expressed economic superiority of topiramate over compara-
tors). Lamotrigine was the most frequent “loser” (45% of all
economic messages). There was at least one message showing
economic superiority over lamotrigine for 7 of the 13 AEDs. For
generically available AEDs, the explanation for cost savings
stemmed from lower drug price, with no evidence of clinical infe-
riority. For levetiracetam, the explanation for cost-effectiveness
stemmed from reduced seizure frequency, a better side effect
proﬁle, and improved adherence. The rationale for topiramate’s
economic advantages was unclear from conference abstracts.
CONCLUSIONS: Several manufacturers of branded AEDs
(Ortho-McNeil, UCB, Novartis) have produced studies describ-
ing their drug’s economic value, while others have done very little
work in this area. Patterns emerge in methods and comparators.
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OBJECTIVE: To assess the cost-effectiveness of pregabalin, a
new add-on antiepileptic, as an adjunct to standard therapy (ST)
in adult patients with refractory partial epilepsy (RPE).
METHODS: We developed a stochastic model to estimate
expected outcomes and costs over one year for a hypothetical
cohort of 1000 RPE patients assumed to receive pregabalin 
(300mg/d, 600mg/d) plus ST or ST alone. Model outcomes
included numbers of days free of seizures (“seizure-free [SF]
days”) and quality-adjusted life-years (QALYs); the latter were
assumed to depend on seizure frequency and side effects. Costs
included those of antiepileptics only. Number of days with
